Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
The project is aimed at identifying how the adrenergic antagonist 'carvedilol' modulates the
effects of sleep deprivation in healthy volunteers. The study is a double-blind, randomized,
placebo-controlled, cross-over study. Investigators will include 20 healthy volunteers who
will undergo three functional magnetic resonance (fMRI) imaging sessions, one at baseline,
and two after sleep deprivation (one night without sleep). The two sleep-deprivation scans
are performed in a randomized order where subjects receive placebo or carvedilol, in a
within-subject, cross-over study design.
The following domains will be described: 1) fMRI imaging of cerebrospinal fluid (CSF)
pulsations (glymphatic flow) in the human brain, performed by a combination of fMRI protocols
that includes structural (T1, T2, diffusion weighted) and functional (multiband/fast imaging,
spectroscopy) imaging. 2) fMRI imaging during wakefulness and sleep are determined by
simultaneous electroencephalographic (EEG) recordings. 3) The effects of sleep deprivation on
the fMRI derived glymphatic flow signal. 4) The effects of the adrenergic antagonist
carvedilol on fMRI measurements and sleep intensity. 5) Quantification of cognitive
performance before and after a nap in the MRI. Cognitive testing includes: assessments of
visual attention, reaction time, paired-associative memory, working memory, emotional
recognition and subjective ratings of sleepiness and mood.
Phase:
Early Phase 1
Details
Lead Sponsor:
Gitte Moos Knudsen
Collaborators:
Center for translational Neuroscience, University of Copenhagen, Denmark Danish Center for Sleep Medicine Danish Center for Sleep Medicine, Rigshospitalet, Denmark